Protein kinases regulate nearly all aspects of cell life, and alterations in their expression, or
mutations in their genes, cause cancer and other diseases. Here, we review the remarkable …

Driver mutations promote initiation and progression of cancer. Pharmacological treatment
can inhibit the action of the mutant protein; however, drug resistance almost invariably …

Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to≥ 2
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …

Chemotherapy is one of the most common treatments for cancer that uses one or more anti-
cancer drugs as a part of the standardized chemotherapy regimen. Cytotoxic chemicals …

Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase
inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant lung cancer, although …

Chronic myeloid leukemia (CML), caused by constitutively active BCR-ABL1 fusion tyrosine
kinase, has served as a paradigm for successful application of molecularly targeted cancer …

For two decades, leukaemia stem cells (LSCs) in chronic myeloid leukaemia (CML) and
acute myeloid leukaemia (AML) have been advanced paradigms for the cancer stem cell …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

From the laboratory perspective, effective management of patients with chronic myeloid
leukemia (CML) requires accurate diagnosis, assessment of prognostic markers, sequential …